TY - JOUR T1 - Symptoms of anxiety and depression and CAT scores in COPD patients entering pulmonary rehabilitation JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P3742 AU - Christina Hilmarsen AU - Sarah Wilke AU - Harald Engan AU - Martijn Spruit AU - Johan Rodenburg AU - Daisy Janssen AU - Sigurd Steinshamn AU - Paul Jones AU - Emiel Wouters AU - Line Oldervoll AU - Frits Franssen Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P3742.abstract N2 - Purpose: Anxiety and depression are common comorbidities in patients with chronic obstructive pulmonary disease (COPD). The present study aimed to assess the impact of anxiety and/or depression on the COPD Assessment Test (CAT), since this is currently unknown.Methods: Demographic and clinical data were recorded in stable patients with mild to very severe COPD entering a Norwegian or a Dutch pulmonary rehabilitation program (PR). Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale, anxiety (HADS-A) and depression (HADS-D) subscales. Scores ≥ 10 points indicated relevant symptoms. Disease specific health status was assessed by the CAT. Scores ranges from 0-40, where a lower score indicates better health. CAT scores, demographic and clinical data were compared between patients without anxiety or depression; with anxiety; with depression; or both. Correlations between HADS subscales and CAT were assessed.Results: The sample consisted of 307 patients (51% male, age 63.9±8.6 years, FEV1 50.0±20.7 % predicted). Patients without anxiety or depression reported significantly lower CAT scores (19.0±6.0), compared to those showing symptoms of anxiety (22.8±6.2, p = 0.02), depression (24.8±6.3, p < 0.001), or both (23.8±8.8, p = 0.002). The CAT score was moderately correlated with HADS-A (r = 0.30, p < 0.001) and HADS-D (r = 0.35, p < 0.001).Conclusion: COPD patients entering PR without anxiety or depression report better disease specific health status measured by CAT than patients with symptoms of anxiety and/or depression.The gathering of the Dutch data was financially supported by the Lung Foundation Netherlands (3.4.10.015) and GlaxoSmithKline (SCO115406). ER -